The article discusses the results of the PATINA study, which investigated the benefit of the CDK4/6 inhibitor palbociclib in patients with HR+ and HER2+ metastatic breast cancer. The addition of palbociclib to standard first-line maintenance therapy significantly prolonged progression-free disease. Median progression-free time was 44.3 months in patients treated with palbociclib in combination with anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy. In patients with anti-HER2 and endocrine therapy alone, this time was 29.1 months, an increase of more than 15 months. Overall survival as a secondary endpoint was not sufficiently evaluated at the time of analysis. About 10% of all breast cancers are HR+ and HER2+, also known as double or triple positive. The results were originally presented at the SABCS Symposium in December 2024.[4]